Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin (Dysferlin)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01863004 |
|
Recruitment Status :
Terminated
(insufficient enrollment rate)
First Posted : May 27, 2013
Last Update Posted : September 21, 2017
|
Sponsor:
University Hospital, Basel, Switzerland
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | September 15, 2017 |
| Actual Study Completion Date : | September 15, 2017 |
Publications of Results:
Azakir BA, Di Fulvio S, Kinter J, Sinnreich M. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J Biol Chem. 2012 Mar 23;287(13):10344-54. doi: 10.1074/jbc.M111.329078. Epub 2012 Feb 8. Retraction in: J Biol Chem. 2017 Jul 28;292(30):12542.
Retraction in:
J Biol Chem. 2017 Jul 28;292(30):12542
Di Fulvio S, Azakir BA, Therrien C, Sinnreich M. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563. doi: 10.1371/journal.pone.0028563. Epub 2011 Dec 8. Retraction in: PLoS One. 2018 Jan 29;13(1):e0192239.
Retraction in:
PLoS One. 2018 Jan 29;13(1):e0192239
Azakir BA, Di Fulvio S, Salomon S, Brockhoff M, Therrien C, Sinnreich M. Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. J Biol Chem. 2012 Aug 10;287(33):27629-36. doi: 10.1074/jbc.M112.391722. Epub 2012 Jun 26. Retraction in: J Biol Chem. 2017 Jul 28;292(30):12543.
Retraction in:
J Biol Chem. 2017 Jul 28;292(30):12543